Gene therapy: Recent progress in the clinical oncology arena

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 4, 2000, Pages 362-375

  Pandha, H S ^a   Martin, L A ^a   Rigg, A S ^a   Ross, P ^a   Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antisense oligonucleotides; Immunotherapy; Prodrug therapy; Tumor; Viral vectors

Indexed keywords

ACICLOVIR; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; CISPLATIN; CYTOKINE; CYTOSINE DEAMINASE; DACARBAZINE; DNA VACCINE; DOCETAXEL; FLUCYTOSINE; FLUOROURACIL; GAMMA INTERFERON; GENE EXPRESSION MODULATOR 231; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; INTERLEUKIN 4; ISIS 2503; ISIS 3521; LEUVECTIN; MG 98; OBLIMERSEN; PACLITAXEL; PHOSPHOROTHIOIC ACID DERIVATIVE; PLASMID DNA; PRODRUG; PROTEIN P53; RECOMBINANT INTERLEUKIN 2; TOPOTECAN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CLINICAL TRIAL; FLU LIKE SYNDROME; GENE; GENE THERAPY; GENE TRANSFER; HUMAN; HYPOTENSION; IMMUNOTHERAPY; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRURITUS; SUICIDE GENE; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE;

ANIMALS; CLINICAL TRIALS; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-B7 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PLASMIDS; PRODRUGS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSDUCTION, GENETIC; VIRUSES;

ADENOVIRIDAE; ARENA;

EID: 0033840743     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Researchers and regulators reflect on first gene therapy death
2. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose boius interleukin 2
3. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autoiogous interleukin 2-transfected cancer cells: Outcome of a phase I study
4. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma
5. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase I clinical trial
6. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
7. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A phase I study
8. Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors
9. Coupling and uncoupling of tumor immunity and autoimmunity
10. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biological activity and lack of toxicity in humans
11. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma
12. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions
13. The dendritic cell system and its role in immunogenicity
14. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines
15. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
16. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
17. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
18. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience
19. Interleukin-4: A prototypic immunoregulatory lymphokine
20. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
21. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
22. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multi-institutional study
23. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T-cell line
24. Inducibility of class II major histocompatibility complex antigens by interferon-γ is associated with reduced tumorigenicity in C3H mouse fibroblasts transformed by v-Ki-ras
25. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or γ interferon
26. Generation of a systemic antitumor response with regional intratumoral injections of interferon-γ retroviral vector
27. A Phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: Monitoring the humoral immune response
28. Phase I trial of retroviral vector-mediated interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma
29. Phase I trial of interferon-γ(IFNγ) retroviral vector administered intratumorally to patients with metastatic melanoma
30. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematological malignancies
31. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS-5132 (CGP 69846A)
32. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS-3521/CGP 64128) in patients with cancer
33. A phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide (G-3139) therapy in patients with non-Hodgkin's lymphoma
34. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
35. Phase I trial of ISIS-5132/ODN 698A, a 20-mer phosphorothioate antisense oligonucleotide inhibitor of c-RAF kinase, administered by a 24 hour weekly intravenous (IV) infusion to patients with advanced cancer
36. A phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS-3521/ISI-641A) delivered as a 24 h continuous infusion (Cl)
37. Bcl-2 antisense therapy in patients with non-Hodgkin's lymphoma
38. Phase I and pharmacokinetic trial of ISIS-2503, a 20-mer antisense oligonucleotide against H-RAS, by 14-day continuous infusion (CIV) in patients with advanced cancer
39. A phase I trial of ISIS-2503, an antisense inhibitor of H-Ras, administered by a 24 h weekly infusion to patients with advanced cancer
40. A phase I and pharmacokinetic (PK) study of human DNA methyltransferase (METASE) antisense oligodeoxynucleotide MG-98 given as a 21-day continuous infusion every 4 weeks
41. Phase I trial of a second generation oligonucleotide (GEM-231) targeted at type I protein kinase a in patients with refractory solid tumors
42. A phase I-II study with dacarbazine and Bcl-2 antisense oligonucleotide G-3139 (GENTA) as a chemosensitizer in patients with advanced malignant melanoma
43. A phase I study of BCL-2 antisense G-3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
44. A phase I trial of G-3139 (Genta Inc), a BCL-2 antisense drug, by continuous infusion (CI) as a single agent and with weekly Taxol
45. Immunostimulatory oligodoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
46. CpG motifs in bacterial DNA trigger direct B-cell activation
47. A phase I trial of ISIS-2503, an antisense inhibitor of H-ras in combination with gemcitabine in patients with advanced cancer
48. A phase I/II trial of ISIS-3521, an antisense inhibitor of protein kinase C-α combined with carboplatin and paclitaxel in patients with non-small cell lung cancer
49. Phase I trial of protein kinase C-α antisense oligonucelotide (ISIS-3521; ISI 641A) with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced cancer
50. A phase I trial of an antisense oligonucleotide to Bcl-2 (G-3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer (HRPC)
51. A matter of life and cell death
52. Cancer cell cycles
53. p53 Tumor suppresser gene therapy for cancer
54. p53-Oriented cancer therapies: Current progress
55. p53 Gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer
56. Gene therapy for head and neck cancer
57. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
58. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
59. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
60. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
61. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
62. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
63. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
64. ONYX-015, An E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
65. The early region 1B 55-kDa oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle
66. p53-Dependent cell death/apoptosis is required for a productive adenovirus infection
67. The replicative capacities of large E1B-nuli group A and group C adenoviruses are independent of host cell p53 status
68. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
69. ONYX-015: Clinical data are encouraging
70. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
71. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
72. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
73. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
74. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
75. Replication-selective adenoviruses as oncolytic agents
76. Onyx plans phase III trial of ONYX-015 for head and neck cancer
77. Conditionally replicating herpes vectors for cancer therapy
78. Replication-selective microbiological agents: Fighting cancer with targeted germ warfare
79. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
80. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically-modified to express cytosine deaminase
81. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
82. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy
83. Herpes simplex thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells
84. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
85. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
86. A Phase I/II study of herpes simplex virus type I thymidine kinase 'suicide' gene therapy for recurrent glioblastoma
87. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration
88. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression
89. A Phase I/II dose-escalation study of herpes simplex virus type I thymidine kinase gene therapy for metastatic melanoma
90. Thymidine kinase (tk) gene therapy of solid tumors: Valacyclovir facilitates outpatient treatment
91. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy In patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
92. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
93. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
94. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors